At the EAHAD Congress in 2024, Hemab Therapeutics Unveils Encouraging Initial Findings for Their Drug, HMB-001, Targeting Glanzmann's Thrombasthenia.

Hydralazine Hydrochloride, marketed under the trade name Dralzine®, is an antihypertensive medication that has been approved since 1952 for the treatment of hypertension.

Chugai Pharmaceutical announced that China's National Medical Products Administration approved its innovative C5 monoclonal antibody, crovalimab.

Colorectal cancer (CRC) ranks second in US cancer deaths. 5-fluorouracil (5-FU) therapies with targeted drugs are the go-to for advanced cases.

In a Phase 2b clinical trial, the experimental oral peptide known as JNJ-2113 has shown encouraging outcomes for patients with moderate to severe psoriasis.

Oxytocin, an OXTR agonist marketed under the trade name OXYTOCIN®, is a medication that has been lauded for its clinical efficacy in the field of obstetrics and gynecology.

REGENXBIO Confirms Major Milestone Reached in Crucial Study of RGX-121 as Therapy for MPS II, Successfully Hitting Primary Goal.

The initial FOLFIRINOX protocol for PDAC carries a high FN risk; pegfilgrastim mitigates this, but optimal duration is uncertain.

Zymedi has begun first human trials of ZMA001, a novel monoclonal antibody for treating Pulmonary Arterial Hypertension.

Dopamine hydrochloride, first approved in the USA on February 25, 1974, is a medication developed and marketed by Hospira.

Encoded Therapeutics Reveals Approval from US FDA for IND Application and Consent from Australian Health Authorities for ETX101, a Genetic Treatment Prospect for Dravet Syndrome.

LY3537982: A Potent Oral Inhibitor for KRAS G12C Mutation in GI Tumors - Results from 2024 ASCO-GI LOXO-RAS-20001 Phase 1 Study.